For Immediate Release

August 5, 2013

Sumitomo Chemical Reports
Consolidated Financial Results
For the Three Months Ended June 30, 2013
The Sumitomo Chemical Group’s consolidated financial results for the first quarter
ended June 30, 2013 were as follows. Sales increased by ¥25.5 billion compared withthe same period of the previous fiscal year, to ¥515.5 billion. The Group posted
operating income of ¥24.6 billion, ordinary income of ¥25.4 billion and net income of¥7.8 billion, all representing year-on-year increases.
The Sumitomo Chemical Group’s financial results by business segment for the firstquarter ended June 30, 2013 were as follows.
Basic Chemicals
Market prices remained low for methyl methacrylate and raw materials for synthetic
fibers, and shipments of these products also remained low. Shipments of aluminum
declined. On the other hand, the correction of the yen’s appreciation had a positiveeffect on sales from overseas subsidiaries in yen terms. As a result, the segment’ssales were almost unchanged from the same period of the previous fiscal year at¥66.8 billion, and there was an operating loss of ¥2.1 billion.
Petrochemicals & Plastics
Market prices of synthetic resins and petrochemical products rose due to higher
feedstock prices. But shipments from overseas subsidiaries decreased due tomaintenance work on the ethane cracker and other factors at Petro Rabigh. The
correction of the yen’s appreciation had a positive effect on sales from overseas
subsidiaries in yen terms. As a result, the segment’s sales totaled ¥177.4 billion,
almost unchanged from the same period of the previous fiscal year, and operating
income increased by ¥2.0 billion, to ¥2.1 billion.
IT-related Chemicals
Sales of polarizing film used in liquid crystal displays (LCDs) increased due to a risein demand. Sales grew as a newly-built touchscreen panel facility in South Korea
began full-fledged operation in the third quarter of the previous fiscal year. As aresult, including the positive effect of the correction of the yen’s appreciation, thesegment’s sales increased by ¥15.8 billion compared with the same period of theprevious fiscal year, to ¥86.1 billion, and operating income grew by ¥8.9 billion, to¥10.0 billion.
Health & Crop Sciences
In the area of crop protection chemicals, shipments of herbicides and other productsrose in overseas markets due to increased production capacity and sales expansion.
Market prices of the feed additive methionine declined. The correction of the yen’s
appreciation had a positive effect on sales from overseas subsidiaries in yen terms.
As a result, the segment’s sales increased by ¥8.8 billion compared with the same
period of the previous fiscal year, to ¥76.0 billion, and operating income grew by ¥1.6billion, to ¥8.1 billion.

Pharmaceuticals
In Japan, in addition to sales of Aimix® (anti-hypertension drug) that was launched
in December last year, sales of Trerief® (therapeutic agent for Parkinson’s disease)and Metgluco® (biguanide oral hypoglycemic) significantly increased. But overallsales declined as a result of a significant decline in shipments of other existingproducts. In North America, shipments of Xopenex® (short-acting beta-agonist)
decreased sharply as marketing exclusivity ended, but shipments of Latuda®
(atypical antipsychotic) continued to rise. The correction of the yen’s appreciation
had a positive effect on sales from overseas subsidiaries in yen terms. As a result,the segment’s sales increased by ¥0.8 billion compared with the same period of theprevious fiscal year, to ¥97.6 billion, and operating income decreased by ¥1.9 billion,to ¥10.7 billion.
OthersIn addition to the above five segments, the Sumitomo Chemical Group engages insupplying electrical power and steam, providing services for the design, engineering,and construction management of chemical plants, providing transport andwarehousing, and conducting materials and environmental analysis. The segment’s
sales remained almost unchanged from the same period of the previous fiscal yearat ¥11.7 billion. Operating income declined by ¥0.3 billion, to ¥0.9 billion.

Summary of Consolidated Results(1) Results of Operations:

Net sales
Operating income
Ordinary income
Income before income taxes
and minority interests
Net income

Net income per 1,000 shares

Comprehensive income(2) Financial Position:
Total assets
Total net asset(3) Cash Flows:

Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period(4) Results of Operations byBusiness Segment:
Net sales
Basic Chemicals
Petrochemicals & Plastics
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersOperating income (loss)
Basic Chemicals
Petrochemicals & Plastics
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments

3 Months ended
June 30，2013
Yen (Millions)
USD (Thousands)*
515,506
5,228,786
24,588249,396
25,403
257,663

3 Months ended
June 30，2012
Yen (Millions)489,959
13,00812,46524,074
7,777

244,183
78,882

10,630904

Yen4,758

USD*
48

Yen553

Yen (Millions)
53,802

USD (Thousands)*
545,715

Yen (Millions)28,415

As of June 30, 2013
Yen (Millions)
USD (Thousands)*
2,626,977
26,645,471
829,813
8,416,807

As of March 31,2013
Yen (Millions)
2,472,091
747,482

3 Months ended
June 30，2013
Yen (Millions)
USD (Thousands)*
7,400
75,058(38,764)(393,184)
39,753403,215
135,497
1,374,348

3 Months ended
June 30，2012
Yen (Millions)
15,063(48,153)
32,912
151,576

3 Months ended
June 30，2013
Yen (Millions)
USD (Thousands)*

3 Months ended
June 30，2012
Yen (Millions)

66,804
177,376
86,05675,99997,61911,652515,506

677,594
1,799,128
872,867
770,859
990,151
118,187
5,228,786

66,554
177,472
70,27067,153
96,837
11,673489,959(2,082)
2,110
10,036
8,133
10,741898(5,248)24,588(21,118)
21,402
101,795
82,493
108,946
9,108(53,230)
249,396(2,543)
108
1,152
6,499
12,625
1,153(5,986)
13,008(Note)*:U.S. dollar amounts are translated from yen, for convenience only, at the rate of¥98.59= $1 prevailing on June 30, 2013.